Navigation Links
Breast cancers behave differently before and after the age of 70
Date:4/18/2008

Berlin, Germany: Researchers in Belgium have discovered that increasing age affects the way breast cancer behaves. As women approach the age of 70, they become less likely to be diagnosed with aggressive tumours that have spread to the lymph nodes. But after 70, the cancer is increasingly likely to spread, particularly if the tumours are small.

Until now, there has been conflicting evidence on aging and lymph node involvement and this study is the first to show clearly how the link between the two changes before and after the age of 70.

Professor Hans Wildiers told the 6th European Breast Cancer Conference (EBCC-6) in Berlin today (Friday), that he suspects that women older than 70 have decreased immune defence mechanisms, which are less able to deal with tumours that are likely to metastasise to other sites in the body.

The effect of age of lymph node positivity is not straightforward. There seems to be a different effect between women aged up to 70 years and women older than 70. For the younger group of women, age appears to have a negative effect on lymph node status the older they become, the less likely the cancer is to have spread to the lymph nodes. For the older group of women (aged over 70), age appears to influence lymph node status in the opposite way the older they become, the more likely they are to have cancer cells in the lymph nodes if the tumour is small, said Prof Wildiers, who is adjunct head of clinic in the department of general medical oncology at the Multidisciplinary Breast Centre, University Hospitals Leuven, Belgium.

There is an interaction between age and tumour size, suggesting that, up to the age of 70, age mainly has a positive effect on lymph node status for older women with small tumours. A likely explanation is that breast tumours metastasise less frequently to lymph nodes with increasing age due to the decreased biological aggressiveness in these tumours. On the other hand, over the age of
'/>"/>

Contact: Emma Mason
wordmason@mac.com
ECCO-the European CanCer Organisation
Source:Eurekalert

0

GOOD

Page: 1 2 3

Related biology news :

1. Herceptin and chemo improves response rates without major adverse effects in HER2 breast cancer
2. New type of drug shrinks primary breast cancer tumors significantly in just 6 weeks
3. New chemotherapy combo produces side effects, but no extra efficacy, in early breast cancer patients
4. Standard chemo works better against metastatic BRCA1/2 breast cancer than against sporadic tumors
5. Pregnant patients lose out in breast cancer treatment; a new approach is needed
6. Improving care and knowledge in translational research to fight breast cancer
7. Evidence now suggests eating soy foods in puberty protects against breast cancer
8. T-cadherin affects blood vessel growth in breast cancer, hormone from fat cells may play a role
9. MU researcher links hormone replacement therapy to breast cancer
10. Gene variant increases breast cancer risk
11. High levels of estrogen associated with breast cancer recurrence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... for Experimental Biology (FASEB) released a new analysis ... highlighting the devastating impact of sequestration on the nation,s ... a May 15th Senate Appropriations Committee hearing featuring NIH ... $1.6 billion cut the agency sustained in FY 2013 ... the scientific community." , According to data from ...
(Date:5/16/2013)... Bethesda, MD FASEB MARC (Maximizing Access to ... recipients for The Society for Developmental Biology (SDB) ... 16-20, 2013. These awards are meant to promote ... underrepresented groups into the mainstream of the basic ... young scientists at the SDB 2013 Annual Meeting. ...
(Date:5/16/2013)... Injectable nanoparticles developed at MIT may someday eliminate ... to constantly monitor their blood-sugar levels and inject ... to sense glucose levels in the body and ... thereby replacing the function of pancreatic islet cells, ... diabetes. Ultimately, this type of system could ensure ...
Breaking Biology News(10 mins):Nanotechnology could help fight diabetes 2Nanotechnology could help fight diabetes 3
... post doctoral fellow Virginie Mieulet, in the Faculty of Medicine ... is so vital in fighting infection. , They have discovered ... body know that it,s being attacked by an infection. , ... could have implications for the millions of people in third ...
... Trypanosomes are parasites responsible for many human and ... parasites cause, African sleeping sickness, results from the bite ... at risk in 36 sub-Saharan countries. The recent 1998-2001 ... of Congo and Uganda killed tens of thousands of ...
... A team led by Massachusetts General Hospital (MGH) scientists ... accurately isolating neutrophils the most abundant type of ... accomplishment that could provide information essential to better understanding ... system, described in a Nature Medicine paper ...
Cached Biology News:New research shows how disease-causing parasite gets around human innate immunity 2New research shows how disease-causing parasite gets around human innate immunity 3New research shows how disease-causing parasite gets around human innate immunity 4Microfluidic device allows collection, analysis of hard-to-handle immune cells 2
(Date:5/20/2013)... , May 20, 2013 Pacific Biomarkers and ... solutions for developers of biosimilars at the 2013 ... Sheraton San Diego Hotel and Marina ... will have the opportunity to speak with company representatives ... Paths That Cross" on May 21 from 1-2 p.m. ...
(Date:5/20/2013)... 20, 2013 Cempra, Inc. (Nasdaq: CEMP), ... antibiotics to meet critical medical needs in the ... presented data at the American Thoracic Society International ... demonstrating the antibacterial and enhanced immunomodulatory activity ... 2 clinical trial in outpatients with community acquired ...
(Date:5/20/2013)... Pittsburgh, PA (PRWEB) May 20, 2013 ... the Allegheny General Hospital (AGH) Cardiovascular Institute ... of coronary artery disease (CAD) over the ... procedures such as balloon angioplasty and coronary artery stent ... will once again play a prominent role in the ...
(Date:5/20/2013)... May 20, 2013 On 25-28 July, ... – in Paris - the beautiful city of lights. ... "Personalized Medicine is revolutionizing the medical world. Understanding and ... is the hallmark of this transformation. Much of the ... from the epidemiologic studies of large cohorts that do ...
Breaking Biology Technology:Pacific Biomarkers and Clinigene International To Announce Laboratory Solutions for Developers of Biosimilars at 2013 AAPS/ National Biotechnology Conference 2Cempra Presents Post-Phase 2 Analysis of Solithromycin's Efficacy and Safety Results from Patients with Community Acquired Bacterial Pneumonia (CABP) 2Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 2Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 3Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 4The International Congress on Personalized Medicine - Up Close and Personalized 2013 in Paris 2
... (Nasdaq:,INSM), today announced that it has been awarded ... (MDA). The grant is expected to cover a,substantial ... 24-week,Phase 3 enabling trial in patients with Myotonic ... biopharmaceutical company with extensive,expertise in biologics and orphan ...
... Filed With the FDA for the Fourth Genmab Antibody ... the Company,s Collaboration with Roche., COPENHAGEN, December 12 ... New Drug application (IND) for a,Genmab antibody developed under ... FDA by Roche. Genentech and Roche are collaborating on,development ...
... Toronto Stock Exchange Symbol: MS, EDMONTON, Dec. ... leading developer in the treatment of multiple sclerosis ... Board (DSMB) has,reviewed data from the Company,s on-going ... for the treatment of secondary progressive MS and,recommended ...
Cached Biology Technology:Insmed Awarded $2.1 Million by Muscular Dystrophy Association 2Insmed Awarded $2.1 Million by Muscular Dystrophy Association 3Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic 2Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic 3BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board 2
... This immunoaffinity purified antibody detects an ... molecular mass of ErbB-2 phosphorylated at tyrosine ... product has been cross adsorbed against the ... detect the non-phosphorylated form of the protein. ...
Anti-GOSR2 Monoclonal AntibodyOther Sub-Family: not assigned-Other Applications: Immunocytochemistry, Immunoprecipitation, Western Blot...
... Synthetic peptide corresponding ... Antigen Family: ... Antigen Subfamily: not ... Recommended Storage: Long ...
Anti-DNA Polymerase a, Human Description: 50 l Research Focus: cancer & cell proliferation Storage: 4C Shipping Temperature: 4C...
Biology Products: